Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Carcinoma, Renal Cell 127Kidney Neoplasms 39Neoplasms 37Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 27Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Stomach Neoplasms 8Neuroendocrine Tumors 8Carcinoma 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Adenoma, Islet Cell 6Uveal Melanoma 5

Interventions

Cyclophosphamide 209fludarabine phosphate 184Azacitidine 159fludarabine 142Busulfan 138Tacrolimus 119Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 106Peripheral Blood Stem Cell Transplantation 98Antilymphocyte Serum 97Melphalan 90Filgrastim 87Cyclosporine 83Decitabine 82Methotrexate 79venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 47Cord Blood Stem Cell Transplantation 42Clofarabine 42thymoglobulin 41Specimen Handling 35Etoposide 35Methylprednisolone 34Sirolimus 33Injections 27Biopsy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Myelodysplastic Syndromes × Sunitinib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00451048 2018-09-04

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡